发明公开
EP2947072A1 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES
有权
![1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES](/ep/2015/11/25/EP2947072A1/abs.jpg.150x150.jpg)
基本信息:
- 专利标题: 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES
- 专利标题(中):1-(3-(6,7-二甲氧基环己烷-4-基)苯基)-3-(5-(1,1,1-三氟-2-甲基丙-2-炔基)异辛基-3-基)乙烯基) 激光调制器ZUR BEHANDLUNG VON KREBSERKRANKUNGEN
- 申请号:EP15166141.0 申请日:2009-03-17
- 公开(公告)号:EP2947072A1 公开(公告)日:2015-11-25
- 发明人: Abraham, Sunny , Bhagwat, Shripad, S. , Campbell, Brian, T. , Chao, Qi , Faraoni, Raffaella , Holladay, Mark, W. , Lai, Andiliy, G. , Rowbottom, Martin, W. , Setti, Eduardo , Sprankle, Kelly, G.
- 申请人: Ambit Biosciences Corporation
- 申请人地址: 4215 Sorrento Valley Boulevard San Diego, CA 92121 US
- 专利权人: Ambit Biosciences Corporation
- 当前专利权人: Ambit Biosciences Corporation
- 当前专利权人地址: 4215 Sorrento Valley Boulevard San Diego, CA 92121 US
- 代理机构: Carpmaels & Ransford LLP
- 优先权: US69763P 20080317; US110508P 20081031
- 主分类号: C07D239/88
- IPC分类号: C07D239/88 ; C07D239/93 ; A61K31/517 ; A61P35/00
摘要:
Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
The compound is 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea, having the structure
or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof.
摘要(中):
The compound is 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea, having the structure
or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof.
提供化合物,组合物和方法用于调节RAF激酶(包括BRAF激酶)的活性,并用于治疗,预防或改善由RAF激酶介导的疾病或病症的一种或多种症状。 化合物是1-(3-(6,7-二甲氧基喹唑啉-4-基氧基)苯基)-3-(5-(1,1,1-三氟-2-甲基丙-2-基)异恶唑-3-基) 尿素,具有结构或其药学上可接受的盐,溶剂合物,包合物或水合物。
公开/授权文献:
IPC结构图谱:
C | 化学;冶金 |
--C07 | 有机化学 |
----C07D | 杂环化合物 |
------C07D239/00 | 杂环化合物,含1,3-二嗪环或氢化1,3-二嗪环 |
--------C07D239/02 | .不与其他环稠合 |
----------C07D239/72 | ..喹唑啉;氢化喹唑啉 |
------------C07D239/74 | ...只有氢原子、烃基或取代烃基,连在杂环的环碳原子上 |
--------------C07D239/88 | ....氧原子 |